Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, Van Bortel L, Dockendorf MF, Tetteh E, Ancona JK, Liu R, Guo Y, Wagner JA, Butterton JR. Anderson MS, et al. Among authors: butterton jr. Antivir Ther. 2015;20(4):397-405. doi: 10.3851/IMP2920. Epub 2014 Dec 3. Antivir Ther. 2015. PMID: 25470746 Clinical Trial.
Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.
Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, Liu R, Anderson MS, Behm MO, Fan L, Li Y, Butterton JR, Iwamoto M, Khalilieh SG. Sanchez RI, et al. Among authors: butterton jr. Xenobiotica. 2019 Apr;49(4):422-432. doi: 10.1080/00498254.2018.1451667. Epub 2018 Mar 28. Xenobiotica. 2019. PMID: 29557716 Clinical Trial.
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.
Yeh WW, Fraser IP, Jumes P, Petry A, Lepeleire I, Robberechts M, Reitmann C, Van Dyck K, Huang X, Guo Z, Panebianco D, Nachbar RB, O'Mara E, Wagner JA, Butterton JR, Dutko FJ, Moiseev V, Kobalava Z, Hüser A, Visan S, Schwabe C, Gane E, Popa S, Ghicavii N, Uhle M, Wagner F. Yeh WW, et al. Among authors: butterton jr. Clin Ther. 2018 May;40(5):704-718.e6. doi: 10.1016/j.clinthera.2018.03.002. Epub 2018 Apr 25. Clin Ther. 2018. PMID: 29703432 Clinical Trial.
Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men.
Caro L, de Hoon J, Depré M, Cilissen C, Miller J, Gao W, Panebianco D, Guo Z, Troemel SL, Anderson MS, Uemura N, Butterton J, Wagner J, Wright DH. Caro L, et al. Clin Transl Sci. 2017 Nov;10(6):480-486. doi: 10.1111/cts.12482. Epub 2017 Aug 10. Clin Transl Sci. 2017. PMID: 28796416 Free PMC article. Clinical Trial.
Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
Hulskotte EG, Feng HP, Xuan F, Gupta S, van Zutven MG, O'Mara E, Wagner JA, Butterton JR. Hulskotte EG, et al. Among authors: butterton jr. Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8. doi: 10.1128/AAC.02347-12. Epub 2013 Mar 25. Antimicrob Agents Chemother. 2013. PMID: 23529734 Free PMC article.
81 results